Search

A 65-year-old woman with a history of bipolar disorder experienced lack of efficacy during treatment for catatonia with amantadine, levodopa/carbidopa, lorazepam, and memantine. Despite receiving multiple treatments, including electroconvulsive therapy, her catatonia remained refractory. Elevated levels of anti-D1 receptor antibodies and anti-tubulin antibodies were found, and she was subsequently treated with immune-globulin and plasmapheresis, which led to improvement. She was discharged with a low BCFRS score. [Extracted from the article]

A 77-year-old man with Parkinson's disease developed constipation while being treated with levodopa/carbidopa. He also experienced a lack of efficacy with domperidone for vomiting and lactulose, sodium-picosulfate, and bisacodyl for constipation. The man's condition worsened, leading to a diagnosis of colonic pseudo-obstruction and sepsis due to bacterial translocation. He was treated with off-label octreotide, metronidazole, and antibiotics, which resulted in significant improvement and normalization of bowel function. [Extracted from the article]

A 70-year-old man experienced drug intolerance while being treated with levetiracetam for corticobasal syndrome (CBS). He also did not experience any clinical benefit from levodopa/carbidopa for CBS. The man met diagnostic criteria for probable CBS and had symptoms of progressive supranuclear palsy, multiple system atrophy, or Parkinson's disease. Initially, he received morphine which improved his symptoms, and he had been receiving botulinum-toxin and clonazepam for pain relief. After receiving scrambler therapy, his clinical condition improved. [Extracted from the article]

A 63-year-old woman with Parkinson's disease developed dyskinesia and depressed level of consciousness due to drug intoxication from amantadine. She had been receiving continuous treatment for Parkinson's disease for 5 years and was admitted for aspiration pneumonia. After starting amantadine, she experienced dyskinesia on day 26 and depressed level of consciousness on day 90. The dose of amantadine was reduced and eventually discontinued, leading to improvement in her symptoms. [Extracted from the article]

This article from Reactions Weekly describes two cases of drug ineffectiveness and side effects in patients with Parkinson's disease (PD). The first case involves a 67-year-old man who experienced drug ineffectiveness with amantadine but had a positive response to levodopa/carbidopa. The second case involves a 60-year-old woman who developed fatigue and staring with both levodopa/carbidopa and levodopa/benserazide, but eventually found relief with a controlled release formula of levodopa/carbidopa. Both patients had a genetic mutation in the GBA gene. This information may be useful for library patrons researching the effectiveness and side effects of different medications for PD. [Extracted from the article]

A 74-year-old woman experienced multiple drug toxicities while being treated for various conditions. She developed parkinsonism, hyperkalemia, inappropriate antidiuretic hormone secretion, hyponatremia, urinary retention, and nausea as side effects of different medications. Her symptoms improved after discontinuing the implicated drugs and receiving appropriate treatment. The woman was advised to increase salt intake and restrict fluids, and she was discharged with a new medication regimen. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events found in scientific literature over the past week. The table includes the drug names, the adverse events, and the number of cases reported. Some examples of adverse events include rectal fistula associated with Abemaciclib, hypersensitivity associated with Abiraterone, and chest pain and vomiting associated with Albendazole and Praziquantel. [Extracted from the article]

A woman in her 70s developed tardive oral dyskinesia while being treated with levosulpiride. Despite receiving treatment with clonazepam, botulinum toxin, and unspecified anticholinergics, her condition did not improve. She also experienced an ischemic stroke on the globus pallidum, but ultimately recovered with no lasting effects and her tardive oral dyskinesia resolved. The woman had pre-existing conditions including diabetes mellitus, hypertension, and hypercholesterolemia. [Extracted from the article]

A 62-year-old man with Parkinson's disease experienced withdrawal symptoms in the form of parkinsonism hyperpyrexia syndrome (PHS) after stopping his medications, including amantadine, trihexyphenidyl, and pramipexole. He also showed a lack of efficacy during treatment with these medications, as well as levodopa/carbidopa. The man had a history of Parkinson's disease, hypertension, and hypothyroidism. After undergoing surgery for a hernia repair, he developed weakness, tremors, difficulty speaking, tachycardia, hypertension, and fever. Resuming his antiparkinsonian medications improved his condition, and he was eventually discharged after 15 days. [Extracted from the article]

A 64-year-old woman experienced drug intoxication after intentionally overdosing on levodopa/carbidopa/entacapone, a medication used to treat Parkinson's disease. She presented with changes in consciousness, hypotension, jaundice, red urine staining, visual hallucinations, and tachycardia. The woman received gastric lavage and activated charcoal therapy, and her condition improved with supportive treatment including oxygen therapy, fluid therapy, and diuretics. She was eventually discharged with improved symptoms. [Extracted from the article]

A 65-year-old woman with Parkinson's disease (PD) developed paranoid psychosis while being treated with levodopa/carbidopa. The woman's psychotic symptoms were a result of the levodopa/carbidopa medication. Her dose was reduced and she was given clozapine, which led to a complete resolution of her psychotic symptoms within 5 months. [Extracted from the article]

A 62-year-old man with Parkinson's disease experienced withdrawal symptoms in the form of parkinsonism hyperpyrexia syndrome (PHS) after stopping his medications, including amantadine, trihexyphenidyl, and pramipexole. He also showed a lack of efficacy during treatment with these medications, as well as levodopa/carbidopa. The man had a history of Parkinson's disease, hypertension, and hypothyroidism. After undergoing surgery for a hernia repair, he developed weakness, tremors, difficulty speaking, tachycardia, hypertension, and fever. Resuming his antiparkinsonian medications improved his condition, and he was eventually discharged after 15 days. [Extracted from the article]

A 64-year-old woman experienced drug intoxication after intentionally overdosing on levodopa/carbidopa/entacapone, a medication used to treat Parkinson's disease. She presented with changes in consciousness, hypotension, jaundice, red urine staining, visual hallucinations, and tachycardia. The woman received gastric lavage and activated charcoal therapy, and her condition improved with supportive treatment including oxygen therapy, fluid therapy, and diuretics. She was eventually discharged with improved symptoms. [Extracted from the article]

A 65-year-old woman with Parkinson's disease (PD) developed paranoid psychosis while being treated with levodopa/carbidopa. The woman's symptoms were resolved after her dosage of levodopa/carbidopa was decreased and she received clozapine. This case highlights a potential side effect of levodopa/carbidopa treatment for PD, but also demonstrates that adjusting the dosage and using alternative medications can effectively manage the symptoms of paranoid psychosis. [Extracted from the article]

A 67-year-old man with Parkinson's disease developed Ogilvie's syndrome, a condition characterized by massive dilatation of the colon, during treatment with levodopa/carbidopa, amantadine, procyclidine, and quetiapine. He presented to the emergency department with increasing abdominal distention, stomach pain, nausea, and abnormal bowel habits. Initial treatment included rectal tube insertion for decompression and potassium replacement, but the caecal diameter remained enlarged. Anticholinergic medications were stopped, and the patient received pyridostigmine and a second trial of colonic decompression, which improved his condition. He was discharged in good condition. [Extracted from the article]

A 67-year-old man with Parkinson's disease developed Ogilvie's syndrome, a condition characterized by massive dilatation of the colon, during treatment with levodopa/carbidopa, amantadine, procyclidine, and quetiapine. He presented to the emergency department with abdominal distention, pain, nausea, and abnormal bowel habits. Initial treatment included rectal tube insertion and potassium replacement, but the caecal diameter remained enlarged. Anticholinergic medications were stopped, and the patient received pyridostigmine and a second trial of colonic decompression, which improved his condition. He was eventually discharged in good condition. [Extracted from the article]

A 27-year-old man with Parkinson's disease (PD) experienced a lack of efficacy with multiple anti-Parkinson's drugs, including levodopa/carbidopa/entacapone, levodopa/benserazide, and pramipexole. Despite intensive medical therapies, his quality of life was severely disrupted. Genetic testing revealed mutations in the PLA2G6 gene. The man underwent surgery for deep brain stimulation (DBS), which resulted in sustained motor benefits and no deterioration in cognitive or psychiatric status. [Extracted from the article]

A 20-year-old man with Wilson's disease experienced a lack of efficacy with multiple medications, including baclofen, gabapentin, clonazepam, trihexyphenidyl, and levodopa/carbidopa, which were being used to treat his spasticity and dyskinesia. Despite receiving maximum doses of these medications, his symptoms persisted. He eventually underwent intrathecal baclofen pump implantation for further management. This case highlights the challenges in finding effective treatments for certain conditions and the need for alternative approaches in managing symptoms. [Extracted from the article]

An 80-year-old man experienced hyperventilation and intravascular depletion while being treated for Parkinson's disease with levodopa/carbidopa and chronic venous congestion with torasemide. He presented to the emergency department with worsening encephalopathy, lethargy, and intermittent hallucinations. Laboratory investigations revealed severe combined respiratory and metabolic alkalosis. The man discontinued levodopa/carbidopa and was treated with chloride-rich saline, acetazolamide, and spironolactone, resulting in the resolution of encephalopathy. [Extracted from the article]

A 15-year-old boy with pediatric-onset multiple sclerosis (POMS) did not respond to treatment with levodopa/carbidopa for Holmes tremor. The boy had been receiving rituximab for POMS with positive results. He had also received various treatments for other conditions, including remdesivir for SARS-CoV-2 infection. Despite trying levodopa/carbidopa, the boy did not experience any therapeutic response and was subsequently started on propranolol. [Extracted from the article]

A 78-year-old woman developed dyskinesia hyperpyrexia syndrome (DHS) while being treated for Parkinson's disease with levodopa/benserazide, pramipexole, and selegiline. The woman was hospitalized after experiencing a coma and hypoglycemia, with no history of diabetes or other relevant conditions. It was determined that levodopa overdose, as well as the combination treatment, contributed to the DHS. After discontinuing pramipexole and reducing the dose of levodopa/benserazide, the woman's symptoms resolved. [Extracted from the article]

A 5-year-old woman with a neurodegenerative disorder experienced a lack of efficacy during treatment with immune-globulin, methylprednisolone, flunarizine, and levodopa/carbidopa. The patient exhibited symptoms such as dystonic posturing, diplopia, dizziness, ataxia, gait instability, hearing loss, urinary urgency, and kyphoscoliosis. Despite receiving various treatments, including IV immune-globulin, IV methylprednisolone, flunarizine, and levodopa/carbidopa, there was no improvement in her symptoms. As a result, off-label treatment with minocycline was attempted due to the progression of her symptoms. [Extracted from the article]

A 22-year-old man experienced dermatological allergic reactions while being treated with levodopa/benserazide for paroxysmal sympathetic hyperactivity. The reactions occurred after the man had been in a car accident and underwent surgery for a fracture. He experienced various complications during his hospitalization, including cardiac arrest, pulmonary embolism, oral bleeding, and pneumonia. After starting levodopa/benserazide, he developed allergic reactions, which improved after the medication was stopped. The man's condition eventually improved, and he was discharged after 52 days of hospitalization. [Extracted from the article]

An 85-year-old man experienced thrombocytopenia and sialorrhoea while being treated with clozapine for Parkinson's disease, and developed dyskinesia while being treated with levodopa. He had a history of Parkinson's disease, REM sleep behavior disorder, prostate cancer, and constipation. The man had been taking multiple medications, including clozapine and levodopa, for his Parkinson's disease. The thrombocytopenia was determined to be a side effect of clozapine, and the sialorrhoea was considered to be a result of the clozapine therapy. The man's condition was being monitored, and he was referred to a hematologist to rule out other causes of thrombocytopenia. [Extracted from the article]

A man in his 60s developed wearing off (WO) and dyskinesia (DK) during treatment with levodopa/carbidopa for Parkinson's disease (PD) and became stiff during treatment with mirtazapine. The man initially showed symptomatic benefit from levodopa/carbidopa but experienced WO within several months. He also received mirtazapine, which made him stiff. His treatment with mirtazapine was discontinued, but his symptoms did not significantly improve. The man was diagnosed with both WO and DK, which were attributed to levodopa/carbidopa. Changes were made to his medication dosages, but his symptoms persisted. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 69-year-old man developed vitamin-B6 deficiency during treatment with levodopa/carbidopa for Parkinson's disease (PD). [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 70-year-old man developed type II and type IV allergy during treatment with levodopa/carbidopa for parkinson's disease [not all routes and dosages stated]. [Extracted from the article]

This document provides a list of drugs associated with non-serious adverse events identified in the scientific literature over the last week. The table includes the drug names, the adverse events reported, and the number of cases. Some of the drugs mentioned include Cannabidiol, Clodronic acid, Doxycycline, Elasomeran, Tozinameran, Furazolidone, Insulin, Lenalidomide, Levodopa/carbidopa, Levofloxacin, Magnesium sulfate, Oxaliplatin, Treprostinil, and Voriconazole. The adverse events range from diaphoresis and tachycardia to injection site pain and delayed hypersensitivity. [Extracted from the article]

A journal article titled "Multiple drugs: Dyskinesia, lack of efficacy and occasional daytime sleepiness" reports on a case involving a young girl who experienced various adverse effects while being treated for different conditions. The girl showed a lack of effectiveness when taking unspecified steroids and pregabalin for dystonia, as well as sodium valproate for depression. Additionally, she developed dyskinesia while being treated with levodopa/carbidopa for Segawa disease and occasional daytime sleepiness while taking sertraline for major depressive disorder. The article does not provide specific details about dosages, durations of treatment, or outcomes. [Extracted from the article]

An adult man developed wearing off phenomenon and dyskinesia while being treated with levodopa and levodopa/carbidopa for Parkinson's disease. He initially received oral levodopa/carbidopa and other medications, but later switched to levodopa/carbidopa intestinal infusion. Despite adjustments to his dosage, he experienced intermittent off periods and increased dyskinesia. The addition of opicapone helped decrease his off time, but also caused moderate dyskinesia and impulsivity. Adjustments to his maintenance dose improved his symptoms, and he continued to receive extra doses of levodopa/carbidopa infusion once or twice a day. [Extracted from the article]

A case report published in Reactions Weekly describes the development of neuroleptic malignant syndrome (NMS) in a 37-year-old man with schizophrenia who was being treated with aripiprazole. The patient experienced parkinsonian symptoms after receiving an injection of aripiprazole and was subsequently diagnosed with NMS. He was treated with bromocriptine and dantrolene, but developed psychiatric complications as a result of the bromocriptine therapy. The patient's psychiatric complications improved after switching to levodopa and continuing dantrolene treatment. [Extracted from the article]

A 73-year-old woman with a history of non-Hodgkin lymphoma, cervical spinal stenosis, and depression developed vertigo while being treated with levodopa/carbidopa for Parkinson's disease. She also experienced a lack of efficacy with levodopa treatment. The woman had a progressive history of imbalance and falls, and had gained weight. Genetic testing later confirmed a diagnosis of GRN-frontotemporal dementia. The woman's family history was significant for dementia as well. [Extracted from the article]

A 55-year-old man experienced dyskinesia hyperpyrexia syndrome (DHS) after misusing and overdosing on levodopa/benserazide, a medication used to treat Parkinson's disease. The man had a history of Parkinson's disease and had been taking levodopa/benserazide for 10 years. He increased his dosage of antiparkinsonian drugs without medical supervision, resulting in an equivalent daily dose of 1750mg of levodopa. He was admitted to the hospital with confusion, involuntary movements, and a high body temperature. Lab tests showed elevated levels of certain enzymes, and an MRI revealed abnormal signals in the brain. The man's treatment was adjusted, and after 2 weeks, he was discharged from the hospital with improved symptoms. [Extracted from the article]